CAR-T In Vitro Efficacy Services with OncoSolid™ Colon Cancer Organoid Models

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Colon Cancer Organoid Models

Colorectal cancer is one of the most common lethal diseases of cancer. To develop potential CAR-cell-based immunotherapy for colorectal cancer treatment to overcome defects of traditional clinical options, models that resemble the tumor tissue physiological characteristics and microenvironment is necessary to test the efficacy of immune cell-based therapies. Creative Biolabs provides a biobank of colorectal cancer organoids that retain the genetics and function diversity of various colorectal carcinoma types to test colorectal targeted CAR-T cells efficacy in vitro.

Fig.1 Scheme of a colon crypt and colon organoids. (Barbáchano, et al., 2021)

Our Colon Cancer Organoid Types

Patient-derived Colorectal Cancer Organoid	Tumor cells are obtained from patients subjected to surgery or endoscopic tests. CRC primary/metastatic tumors.
Primary Mouse Colon Tumors Organoid	Tumor organoids derived from genetically modified mice. Organoids are amendable to editing cancer-related genes, such as deficient for Apc or double knock‐out for Rnf43/Znrf3.
CRISPR/Cas9 Edited Human Colorectal Cancer Organoid	CRISPR-Cas9 mediated tumor suppressor genes mutation, such as APC, SMAD4, and TP53, and the oncogenes KRAS and PI3KCA.

Complete Characterization of Colorectal Cancer Organoids

Fig.2 Characterizing organoids using various methods. (Creative Biolabs)

Key Features of the CAR-T Efficacy Evaluation Service

Fig.3 Highlight features of our colon cancer organoid model. (Creative Biolabs)

Colon Cancer Targeted CAR-T Products Available for Anti-tumor Efficacy Test

Creative Biolabs provides the following antigen-targeted CAR-T products for anti-tumor efficacy test using cancer organoid models.

Target Antigen	Target Description	CAR-T Products
CEA	CEA is a antigen marker of colorectal cancer, and is overexpressed in nearly 80% of diagnosed patients.	Anti-CEA CAR-T
EpCAM	Epithelial cell adhesion molecule (EpCAM) is expressed in kinds of human cancers, especially in metastatic stage of cancers.	Anti-EpCAM CAR-T
NKG2D	Instead of protection function, overexpression of NKG2D in colorectal cancer is related to poor survival of patients and can be targeted by CAR-T cells.	Anti-NKG2D CAR-T
GUCY2C	Guanylyl cyclase C (GUCY2C) is a membrane-bound receptor maintains in >95% of colorectal cancer metastases, and it is ectopically expressed in tumors that evolve from intestinal metaplasia, including esophageal, gastric, and pancreatic cancers.	Anti-GUCY2C CAR-T
CD46	CD46 is a membrane protein that overexpressed in multiple human cancers, including prostate cancer, colon cancer, breast cancer, ovarian cancers, and hepatocellular carcinomas.	Anti-CD46 CAR-T
TAG72	Tumor associated glycoprotein 72 (TAG-72) is an oncofetal mucin overexpressed in multiple human cancer cells, such as colon, breast, pancreas, and stomach.	Anti-TAG72 CAR-T

CAR-T Related Products	CAR-T Development Services
CAR Vector Products CAR Cells CAR-viral Particle Products CAR Jurkat Cell Products CAR Lentivirus Packaging Kit Kits for CARs/TCRs Development CARMA Vector Products CARMA Cell Products	One-Stop CAR-T Therapy Development services CAR Design & Construction CAR-T Gene Packaging & Delivery CAR Cell In Vitro Assay Service CAR-T Preclinical In Vivo Assay

Case Study

Applying Patient-Derived Colorectal Cancer Organoids to CAR-NK Cell Efficacy Test
Target: Normal and tumor organoids of colon derived from the patient are transduced with lentivirus containing the luciferase gene Effector cell: EPCAM NK Cell Co-culture: CAR-NK cells and organoids co-cultured on Matrigel Cytotoxicity assay: Detect luciferase activity retained in cells
Fig.4 Measure the luciferase activity in organoids to determine CAR-NK92 cell cytotoxicity. (Schnalzger, et al., 2019)	Fig.5 Image analysis of the single organoid area and total organoid area at continuous time points while co-culturing. (Schnalzger, et al. 2019)

Creative Biolabs is committed to offering advanced organoids technology for cancer research and investigation of tumor responses to CAR-T therapies. Please contact us and find out how we can help you.

References

Schnalzger, T. E.; et al. 3D model for CAR-mediated cytotoxicity using patient-derived colorectal cancer organoids. The EMBO journal. 2019, 38(12): e100928.
Barbáchano, A.; et al. Organoids and Colorectal Cancer. Cancers. 2021, 13(11): 2657.